Lentigo maligna melanoma - Biotech, Pharma and Life Science Channel
PubMed Articles
Tumor lysis syndrome and malignant melanoma.
Tumor lysis syndrome (TLS) is an oncological emergency that results from massive cytolysis of malignant cells with a sudden release of their contents into the systemic circulation. TLS was rarely desc...
BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD), elevated in tumor cells, catalyzes the first reaction in the pentose-phosphate pathway. The regulation mechanism of G6PD and pathological change i...
Over the past few decades, Fourier transform infrared (FTIR) spectroscopy coupled to microscopy has been recognized as an emerging and potentially powerful tool in cancer research and diagnosis. For t...
Abstract Both chronic stress conditions and hyperergic reaction to environmental stress are known to enhance cancer susceptibility. We described two mouse lines that displayed high (HA) and low (LA) s...
The development of exosomes as delivery vehicles requires understanding how and where exogenously administered exosomes are distributed in vivo. In the present study, we designed a fusion protein cons...
The majority of human melanoma cell lines secretes vascular endothelial growth factor-A (VEGF-A) and expresses its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP‑1), a co-receptor for VEGF-A that...
Clinical effects of stereotactic radiation surgery in patients with metastatic melanoma.
We examined the effectiveness of stereotactic radiation surgery (SRS) in 14 patients with brain metastasis in our hospital. The age of the patients ranged 45-85 years old (mean, 65). Brain metastasis...
A multifunctional nanoplatform with four-in-one photoresponsive functionalities has been achieved through the co-encapsulation of two chromo-fluorogenic components within biocompatible polymeric nanop...
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions.
Melanoma is increasing in incidence and remains a major public health threat. Although the disease may be curable when identified early, advanced melanoma is characterized by widespread metastatic dis...
PURPOSE: Results of the association between non-steroidal anti-inflammatory drugs (NSAIDs) and melanoma risk have been inconsistent. We performed a meta-analysis of relevant studies to investigate the...
News Articles
NEW YORK, May 23, 2013 /PRNewswire/ -- Memorial Day is around the corner and rising temperatures are sure to follow. In advance of beach season, SkinCeuticals and a cas...
More patients than docs report skin surgery problems
NEW YORK (Reuters Health) - More than one quarter of people being treated for non-melanoma skin cancer in their doctor's office reported some type of complication after surgery, in a new study.
Cancer Research Institute Hosting Free Cancer Immunotherapy Webinars in June
NEW YORK, May 22, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, is holding a series o...
Oncolytics cancer drug meets mid-stage trial goal, shares rise
(Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic mela...
BRIEF-Oncolytics Biotech U.S.-listed shares jump 10.3 percent premarket
NEW YORK, May 22 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares jump 10.3 percent to $3 in premarket after phase 2 metastatic melanoma trial results
CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metasta...
Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence i...
Merck's Novel Immunotherapy Drug Receives 'Breakthrough Therapy Designation'
By The Swiss Trader:In April the global health care giant Merck & Co. (MRK), received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for its investigational an...
CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastat...
Events
None
Companies
Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells...
After losing her Mother to melanoma skin cancer, which claims nearly 8,650 people each year, Founder Tricia Trimble recognized the importance of proper sun protection. More import...
Cascade Technologies Corp., through its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI), is a development-stage medical imaging device company, applying its proprie...
Cascade Technologies Corporation
Cascade Technologies Corp., through its wholly owned subsidiary Spectral Molecular Imaging, Inc., is a development-stage, medical imaging device company, applying its proprietary...
Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targete...
The mission of CollabRx is to save lives by using information technology (IT) to personalize cancer treatments and accelerate research. Our web-based applications and services pow...
AIM at Melanoma, founded in memory of Charlie Guild, who died of melanoma at the age of 26, is the largest international melanoma foundation focused on melanoma research, patient...
Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynomaâs lead product candidate is the therapeutic vaccine POL...
Malignant melanoma is the most serious form of skin cancer. An estimated 200,000 new cases of melanoma are diagnosed annually around the world, with about 76,000 in the United Sta...
Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The companyâs lead compound, PLX4032,...
Clinical Trials
This is an open-label, dose-escalation, non-randomized, phase I study in patients with histologically confirmed Stage III or IV melanoma and at least three metastatic cutaneous or subcutan...
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interfe...
PS-341 With Oral Temozolomide in Patients With Advanced Refractory Solid Tumors or Melanoma
Patients are asked to participate in this research because they have been diagnosed as having cancer that is not curable by any standard means including surgery or radiation therapy or oth...
Pegylated Interferon-Alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant...
This is a study of a melanoma vaccine. Study participants will have melanoma that invaded deeply and spread to lymph nodes or another location. Although the participants' melanoma has be...
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
This study evaluates a cancer vaccine in melanoma patients who have resected melanoma but are at high risk for recurrence (stages IIB-III). This is a single arm, open label, pilot/phase I...
RATIONALE: An infusion of a patient's lymphocytes that have been treated in the laboratory to remove certain immune cells may be an effective treatment for melanoma. Drugs, such as cycloph...
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment...
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is st...
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is stu...
Videos
Skin Cancer Lentigo Maligna Melanoma
Dr. James L. Campbell Jr., MD discusses Skin Cancer Lentigo Maligna Melanoma. See more at http://www.dermnet.com PLEASE RATE AND COMMENT!!! Lentigo maligna a...
Medical and Biotech [MESH] Definitions
Leopard Syndrome
An autosomal dominant disorder with an acronym of its seven features (LENTIGO; ELECTROCARDIOGRAM abnormalities; ocular HYPERTELORISM; PULMONARY STENOSIS; abnormal genitalia; retardation of growth; and DEAFNESS or SENSORINEURAL HEARING LOSS). This syndrome is caused by mutations of PTPN11 gene encoding the non-receptor PROTEIN TYROSINE PHOSPHATASE, type 11, and is an allelic to NOONAN SYNDROME. Features of LEOPARD syndrome overlap with those of NEUROFIBROMATOSIS 1 which is caused by mutations in the NEUROFIBROMATOSIS 1 GENES.
Melanoma-specific Antigens
Cellular antigens that are specific for MELANOMA cells.
Gp100 Melanoma Antigen
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Mart-1 Antigen
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Iris Neoplasms
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.
